Payment overview · 2025
General Payments
$3,599.16
123 reported records · 23 companies
Healthcare provider profile · identity verified
Carlos E Picone, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · CHEVY CHASE, MD · NPI 1861475840
Verified facts
What the public records show
CMS Open Payments records show Carlos E Picone, M.D. received $3,599.16 in general payments during 2025 across 123 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Adempas, Mounjaro, Ofev, Opsumit, Paxlovid, Trelegy Ellipta.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Opsumit by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 3385 records involving 1868 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Adempas by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 296 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $901.84 | 25.1% | 25 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $742.02 | 20.6% | 24 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $347.48 | 9.7% | 14 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $212.28 | 5.9% | 7 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $195.96 | 5.4% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $153.55 | 4.3% | 8 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $150.56 | 4.2% | 5 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $117.09 | 3.2% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $99.95 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $97.78 | 2.7% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $78.84 | 2.2% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $75.30 | 2.1% | 3 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $68.21 | 1.9% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $63.07 | 1.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.42 | 1.3% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $44.56 | 1.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.38 | 1.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.80 | 1.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.40 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.80 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.39 | 0.7% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $23.15 | 0.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.33 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,499.21 | 122 |
| Education | $99.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $524.45 | 15 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $446.47 | 11 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $347.48 | 14 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $334.10 | 10 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $324.90 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $217.57 | 9 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $212.28 | 7 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $153.55 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $149.46 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $137.76 | 6 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $117.09 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $78.84 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $75.30 | 3 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $68.21 | 3 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $63.07 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $56.13 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $56.13 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $56.13 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $52.02 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $44.56 | 3 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.80 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.65 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.40 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| Veklury Normalized: veklury |
Drug | Gilead Sciences, Inc. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $6.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Adempas adempas |
2025 | Adempas | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 97 | exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 29 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 296 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 3385 supporting records · 1868 recipient NPIs · example record 1225434673 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
296 | 103 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
97 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 431 | 198 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 327 | 101 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 296 | 103 |
| Cefuroxime | Cefuroxime Axetil | 282 | 150 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 166 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 45 |
| Furosemide | Furosemide | 120 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 114 | 34 |
| Montelukast Sodium | Montelukast Sodium | 114 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 40 |
| Metformin Hcl Er | Metformin Hcl | 100 | 36 |
| Mounjaro | Tirzepatide | 97 | 15 |
| Trazodone Hcl | Trazodone Hcl | 94 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 93 | 33 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 93 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 89 | 31 |
| Ipratropium Bromide | Ipratropium Bromide | 86 | 46 |
| Spironolactone | Spironolactone | 84 | 35 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 78 | 27 |
| Celecoxib | Celecoxib | 77 | 33 |
| Azithromycin | Azithromycin | 76 | 54 |
| Breo Ellipta | Fluticasone/Vilanterol | 76 | 25 |
| Eplerenone | Eplerenone | 76 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 67 | 40 |
| Fluconazole | Fluconazole | 65 | 28 |
| Finasteride | Finasteride | 64 | 20 |
| Jardiance | Empagliflozin | 64 | 21 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 62 | 25 |
| Losartan Potassium | Losartan Potassium | 57 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 23 |
| Omeprazole | Omeprazole | 46 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 34 |
| Ondansetron Odt | Ondansetron | 44 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 16 |
| Ofev | Nintedanib Esylate | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | 14 |
| Levofloxacin | Levofloxacin | 40 | 21 |
| Simvastatin | Simvastatin | 40 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 30 |
| Eliquis | Apixaban | 38 | 14 |
| Mirtazapine | Mirtazapine | 38 | 14 |
| Sertraline Hcl | Sertraline Hcl | 37 | 12 |
| Azelastine Hcl | Azelastine Hcl | 36 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 14 |
| Methylprednisolone | Methylprednisolone | 35 | 23 |
| Alprazolam | Alprazolam | 34 | 18 |
| Torsemide | Torsemide | 32 | 12 |
| Allopurinol | Allopurinol | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Clonidine | Clonidine | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 12 |
| Tadalafil | Tadalafil | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 15 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Estradiol | Estradiol | 25 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | 11 |
| Tramadol Hcl | Tramadol Hcl | 24 | 12 |
| Irbesartan | Irbesartan | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 21 | 14 |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | 11 |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 14 |
| Minoxidil | Minoxidil | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Metformin Hcl | Metformin Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Gabapentin | Gabapentin | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lisinopril | Lisinopril | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Opsumit | Macitentan | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Adempas | Riociguat | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,599.16 · 123 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Adempas, Arikayce, BREZTRI, Brinsupri, COMIRNATY, Cologuard Collection Kit, DUPIXENT, FASENRA, INSPIRE, MOUNJARO, NUCALA, NURTEC ODT, OFEV, OPSUMIT, Ohtuvayre, PAXLOVID, PREVNAR 20, Prolastin-C Liquid, SMARTVEST, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, UPTRAVI, Veklury, WAKIX, XYWAV, YUPELRI, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Adempas play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error